Quarterly report [Sections 13 or 15(d)]

Restructuring (Details)

v3.25.3
Restructuring (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
USD ($)
installment
Jun. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
Restructuring        
Recovery of assets held-for-sale $ 6,789      
Fair Value, Recurring | Other Noncurrent Assets        
Restructuring        
Notes receivable 7,744 $ 2,184   $ 2,184
Restructuring Plan to Optimize Global Manufacturing        
Restructuring        
Restructuring reserve, beginning of period 1,101      
Restructuring costs 125 95,631    
Cash payments (5,046)      
Non-cash adjustments 6,789 (94,530)    
Restructuring reserve, end of period 2,969 1,101   1,101
Restructuring Plan to Recover Operating Margins        
Restructuring        
Restructuring reserve, beginning of period 1,222      
Restructuring costs $ 597   $ 10,269 4,148
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Cost of Goods and Services Sold      
Cash payments $ (1,024)     (3,354)
Non-cash adjustments       (9,841)
Restructuring reserve, end of period 795 1,222   1,222
Protein Sciences | Restructuring Plan to Optimize Global Manufacturing        
Restructuring        
Restructuring costs 3,208      
Protein Sciences | Restructuring Plan to Recover Operating Margins        
Restructuring        
Restructuring costs 597   9,691  
Diagnostics and Spatial Biology | Restructuring Plan to Optimize Global Manufacturing        
Restructuring        
Restructuring costs (3,823)      
Diagnostics and Spatial Biology | Restructuring Plan to Recover Operating Margins        
Restructuring        
Restructuring costs     444  
Exosome Diagnostics | Disposed of by Sale | Restructuring Plan to Optimize Global Manufacturing        
Restructuring        
Consideration for sale 15,000      
Consideration as stock 6,800      
Recovery of assets held-for-sale $ 6,800      
No. of installments | installment 4      
Installment amount $ 2,500      
Stock consideration receivable 5,000      
Exosome Diagnostics | Disposed of by Sale | Restructuring Plan to Optimize Global Manufacturing | Fair Value, Recurring        
Restructuring        
Notes receivable 9,000      
Exosome Diagnostics | Held for sale | Restructuring Plan to Optimize Global Manufacturing        
Restructuring        
Goodwill attributable to disposal group held for sale   4,500   4,500
Cumulative impairment charge   83,100    
Corporate | Restructuring Plan to Optimize Global Manufacturing        
Restructuring        
Restructuring costs 740      
Corporate | Restructuring Plan to Recover Operating Margins        
Restructuring        
Restructuring costs     134  
Cost of Sales | Restructuring Plan to Optimize Global Manufacturing        
Restructuring        
Restructuring costs 1,482      
Cost of Sales | Restructuring Plan to Recover Operating Margins        
Restructuring        
Restructuring costs     4,898  
Selling, General and Administrative Expenses | Restructuring Plan to Optimize Global Manufacturing        
Restructuring        
Restructuring costs (1,357)      
Selling, General and Administrative Expenses | Restructuring Plan to Recover Operating Margins        
Restructuring        
Restructuring costs     5,371  
Employee severance | Restructuring Plan to Optimize Global Manufacturing        
Restructuring        
Restructuring reserve, beginning of period 1,041      
Restructuring costs 5,342 1,041    
Cash payments (3,414)      
Restructuring reserve, end of period 2,969 1,041   1,041
Employee severance | Restructuring Plan to Recover Operating Margins        
Restructuring        
Restructuring reserve, beginning of period 1,222      
Restructuring costs 420   2,852 593
Cash payments (847)     (2,223)
Restructuring reserve, end of period 795 1,222   1,222
Employee severance | Protein Sciences | Restructuring Plan to Optimize Global Manufacturing        
Restructuring        
Restructuring costs 1,636      
Employee severance | Protein Sciences | Restructuring Plan to Recover Operating Margins        
Restructuring        
Restructuring costs 420   2,274  
Employee severance | Diagnostics and Spatial Biology | Restructuring Plan to Optimize Global Manufacturing        
Restructuring        
Restructuring costs 2,966      
Employee severance | Diagnostics and Spatial Biology | Restructuring Plan to Recover Operating Margins        
Restructuring        
Restructuring costs     444  
Employee severance | Corporate | Restructuring Plan to Optimize Global Manufacturing        
Restructuring        
Restructuring costs 740      
Employee severance | Corporate | Restructuring Plan to Recover Operating Margins        
Restructuring        
Restructuring costs     134  
Asset-related and other | Restructuring Plan to Optimize Global Manufacturing        
Restructuring        
Restructuring reserve, beginning of period 60      
Restructuring costs 1,572 11,531    
Cash payments (1,632)      
Non-cash adjustments   (11,471)    
Restructuring reserve, end of period   60   60
Asset-related and other | Restructuring Plan to Recover Operating Margins        
Restructuring        
Restructuring costs 177   7,417 3,555
Cash payments (177)     (1,131)
Non-cash adjustments       $ (9,841)
Asset-related and other | Protein Sciences | Restructuring Plan to Optimize Global Manufacturing        
Restructuring        
Restructuring costs 1,572      
Asset-related and other | Protein Sciences | Restructuring Plan to Recover Operating Margins        
Restructuring        
Restructuring costs 177   $ 7,417  
Impairment (Recovery) Of Assets Held For Sale [Member] | Restructuring Plan to Optimize Global Manufacturing        
Restructuring        
Restructuring costs (6,789) 83,059    
Non-cash adjustments 6,789 $ (83,059)    
Impairment (Recovery) Of Assets Held For Sale [Member] | Diagnostics and Spatial Biology | Restructuring Plan to Optimize Global Manufacturing        
Restructuring        
Restructuring costs $ (6,789)